Neurocrine Biosciences, Inc.
VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF

Last updated:

Abstract:

Provided is a compound selected from compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof: (I) wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, neurological and psychiatric diseases and disorders. Also disclosed are compositions containing such compounds in combination with a pharmaceutically acceptable carrier, as well as methods relating to their use in subjects in need thereof. ##STR00001##

Status:
Application
Type:

Utility

Filling date:

17 Apr 2018

Issue date:

30 Apr 2020